20th week of 2014 patent applcation highlights part 52 |
Patent application number | Title | Published |
20140135329 | Pyridine and Pyrazine derivative for the Treatment of CF - The present invention provides pyridine and pyrazine derivatives which restore or enhance the function of mutant and/or wild type CFTR to treat cystic fibrosis, primary ciliary dyskinesia, chronic bronchitis, chronic obstructive pulmonary disease, asthma, respiratory tract infections, lung carcinoma, xerostomia and keratoconjunctivitis sire, or constipation (IBS, IBD, opioid induced). Pharmaceutical compositions comprising such derivatives are also encompassed. | 2014-05-15 |
20140135330 | Oxazolidin-2-one-Pyrimidine Derivatives - The present invention relates to oxazolidin-2-one substituted pyrimidine compounds that act as PI3K (phosphatidylinositol-3-kinase) inhibitors, as well as pharmaceutical compositions thereof, methods for their manufacture and uses for the treatment of conditions, diseases and disorders dependent on PI3K. | 2014-05-15 |
20140135331 | THIAZOLE AND THIADIAZOLE COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES - The invention relates to compounds of structural formula (I): | 2014-05-15 |
20140135332 | AROMATIC AMIDES AND USES THEREOF - The present invention provides compounds of Formula (I): and salts, racemates, isomers, diastereoisomers, enantiomers, hydrates, solvates, N-oxides, pharmaceutically acceptable derivatives or prodrugs thereof. Also provided the use of these compounds as antibacterials, compositions comprising them and processes for their manufacture. | 2014-05-15 |
20140135333 | DUAL-ACTING THIOPHENE, PYRROLE, THIAZOLE AND FURAN ANTIHYPERTENSIVE AGENTS - In one aspect, the invention relates to compounds having the formula: | 2014-05-15 |
20140135334 | COMPOSITIONS OF DIBROMOMALONAMIDE AND THEIR USE AS BIOCIDES - A biocidal composition comprising 2,2-dibromomalonamide and an aldehyde-based biocidal compound, and its use for the control of microorganisms in aqueous and water-containing systems. | 2014-05-15 |
20140135335 | SPIRO BICYCLIC OXALAMIDE COMPOUNDS FOR THE TREATMENT OF HEPATITIS C - Compounds of Formula I, including pharmaceutically acceptable salts, as well as compositions containing these compounds, have activity against hepatitis C virus (HCV) and may be useful in treating those infected with HCV: | 2014-05-15 |
20140135336 | TRIAZOLOPYRIDAZINE - Disclosed are compounds of general formula (I) | 2014-05-15 |
20140135337 | INDUCTION OF IMMUNE TOLERANCE BY USING METHOTREXATE - The invention provides methods for reducing undesired immune responses, such as anti-drug antibody (ADA) responses and other T- and/or B-cell-mediated immune responses, in patients by using treatment with methotrexate. | 2014-05-15 |
20140135338 | QUINOLINYL GLUCAGON RECEPTOR MODULATORS - The present invention provides a compound of Formula I or a pharmaceutically acceptable salt thereof, wherein R | 2014-05-15 |
20140135339 | MACROCYCLIC DERIVATIVES FOR THE TREATMENT OF DISEASES - The invention relates to compounds of formula (Φ) | 2014-05-15 |
20140135340 | High Drug Load Tablet - The present invention pertains to a high drug load tablet comprising an active ingredient Compound I of formula | 2014-05-15 |
20140135341 | Pyridine And Pyrimidine Derivatives As Inhibitors Of Histone Deacetylase - This invention comprises the novel compounds of formula (I) | 2014-05-15 |
20140135342 | PHARMACEUTICAL FORMULATIONS OF SUBSTITUTED AZAINDOLEOXOACETIC PIPERAZINE DERIVATIVES WITH PROTEASE INHIBITORS - This invention provides compounds having drug and bio-affecting properties, their pharmaceutical compositions and method of use. In particular, the invention is concerned with azaindoleoxoacetyl piperazine derivatives. These compounds possess unique antiviral activity, whether used alone or in combination with other antivirals, antiinfectives, immunomodulators or HIV entry inhibitors. More particularly, the present invention relates to the treatment of HIV and AIDS. | 2014-05-15 |
20140135343 | ARIPIPRAZOLE MEDICAMENT FORMULATION AND PREPARATION METHOD THEREFOR - The preparation method includes the following steps: dissolving aripiprazole in an acidic solution having an acidifier so as to obtain a medicament having acidic solution; then, performing a wet granulation on or preparing a suspension with the obtained medicament having acidic solution, an alkalizer, and an excipient so as to obtain the aripiprazole medicament formulation; the excipient comprising an antioxidant. The aripiprazole medicament formulation obtained through the preparation method has a significantly reduced amount of related substances, great solubility, great stability, high bioavailability, reduced individual differences, and enhanced wettability and content uniformity of insoluble medicaments. | 2014-05-15 |
20140135344 | ARIPIPRAZOLE TYPE I MICROCRYSTAL, ARIPIPRAZOLE SOLID PREPARATIONS, AND PREPARATION METHOD - A method for preparing an aripiprazole type I microcrystal, including the following steps: dissolving aripiprazole in an acidifier, acquiring a medicament-having acid solution; adding an alkalizer while stirring, then adding water or aqueous ethanol 10 to 60 wt % while stirring, and separating by precipitation the aripiprazole type I microcrystal. Furthermore, a method for preparing a solid preparation having the aripiprazole type I microcrystal, an aripiprazole microcrystal having an average particle size of less than 24 μm, and a solid preparation having the microcrystal. The method for preparing the aripiprazole type I microcrystal allows reduced pollution and loss, great safety, easy and convenient, reduced use of organic solvents, obviated need for demanding process conditions (such as cooling condition) and apparatus, low cost, and facilitated applicability in industrialized manufacturing. This solid preparation provides great stability, solubility, and bioavailability, reduced individual differences, and reduced content of related substances. | 2014-05-15 |
20140135345 | CRYSTALLINE FORMS AND PROCESSES FOR THE PREPARATION OF CANNABINOID RECEPTOR MODULATORS - The present invention relates to crystalline forms of (1aS,5aS)-2-(4-oxy-pyrazin-2-yl)-1a,2,5,5a-tetrahydro-1H-2,3-diaza-cyclopropa[a]pentalene-4-carboxylic acid ((S)-1-hydroxymethyl-2,2-dimethyl-propyl)-amide (Compound 1) and pharmaceutical compositions thereof that modulate the activity of the cannabinoid CB | 2014-05-15 |
20140135346 | Novel Heterocyclic Compounds as Pesticides - The present application relates to novel amides and thioamides, to processes for preparation thereof and to the use thereof for controlling animal pests, in particular arthropods and especially insects. | 2014-05-15 |
20140135347 | INHIBITORS OF BRUTON'S TYROSINE KINASE - Disclosed herein are compounds that form covalent bonds with Bruton's tyrosine kinase (Btk). Also described are irreversible inhibitors of Btk. Methods for the preparation of the compounds are disclosed. Also disclosed are pharmaceutical compositions that include the compounds. Methods of using the Btk inhibitors are disclosed, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, and inflammatory diseases or conditions. | 2014-05-15 |
20140135348 | USES OF DPP IV INHIBITORS - The specification describes the use of selected DPP IV inhibitors for the treatment of physiological functional disorders and for reducing the risk of the occurrence of such functional disorders in at-risk patient groups. In addition, the use of the above-mentioned DPP IV inhibitors in conjunction with other active substances is described, by means of which improved treatment outcomes can be achieved. These applications may be used to prepare corresponding medicaments. | 2014-05-15 |
20140135349 | Aqueous Compositions - Suggested is a non-therapeutic aqueous composition for topical application, comprising
| 2014-05-15 |
20140135350 | SUSTAINED-RELEASE DOSAGE FORMS OF RUXOLITINIB - The present invention relates to sustained-release formulations and dosage forms of ruxolitinib, or a pharmaceutically acceptable salt thereof, which are useful in the treatment of Janus kinase-associated diseases such as myeloproliferative disorders. | 2014-05-15 |
20140135351 | Benzomorphan Analogs and the Use Thereof - The present invention is directed to Benzomorphan Analog compounds of the Formula I″, Formula IA″, Formula IB″, Formula IC″, or Formula ID″ as shown below; and related Formula I′, Formula IA′, Formula IB′, Formula IC′, or Formula ID′; Formula I, Formula IA, Formula IB, Formula IC, or Formula ID; wherein R | 2014-05-15 |
20140135352 | TABLET HAVING IMPROVED ELUTION PROPERTIES - The present invention provides a tablet having improved dissolution property, which comprises (+)-3-{1-[3-(trifluoromethoxy)benzyl]piperidin-4-yl}-4-phenyl-3,4-dihydro-2(1H)-quinazolinone or a pharmaceutically acceptable salt thereof as an active component, and a production method thereof. A film-coated tablet obtained by mixing granulated particles obtained by granulating a mixture containing (a) the aforementioned active component, (b) one or more kinds of fillers selected from lactose, D-mannitol, erythritol and crystalline cellulose, (c) a cellulose-based disintegrant and (d) a water-soluble binder with a later powder containing (e) one or more kinds of fillers selected from lactose, D-mannitol and crystalline cellulose and/or (f) a cellulose-based disintegrant, forming the mixture, and applying film coating. A production method of a film-coated tablet, including a step of producing the granulated particles, a step of producing a tablet by mixing with the later powder and forming the mixture, and a step of applying a film coating to the obtained tablet. | 2014-05-15 |
20140135353 | CRYSTALLINE SODIUM SALT OF AN HIV INTEGRASE INHIBITOR - A crystalline sodium salt of a compound of formula I (INN: Raltegravir) | 2014-05-15 |
20140135354 | TETRANDRINE PHARMACEUTICAL FORMULATIONS AND METHOD - Drug formulations, methods and their use in treatment of diseases using the free base formulations of tetrandrine family members, especially d-tetrandrine, combined with a pharmaceutical diluent or carrier. | 2014-05-15 |
20140135356 | Novel Analogs of Camptothecin - The present invention provides novel conjugates of camptothecin and camptothecin analogs with a linker and an HSA-binding moiety. The novel conjugates are prodrug forms of the camptothecin or camptothecin analogs and can be used to treat mammalian cell proliferative diseases, such as cancer. | 2014-05-15 |
20140135357 | DOSE REGIME FOR CAMPTOTHECIN DERIVATIVES - The present invention is directed to a method of inhibiting cancer cell growth, comprising administering a pharmaceutical composition to a subject in need thereof. The pharmaceutical composition comprises at least one camptothecin derivative or a pharmaceutically acceptable salt thereof; and at least one PEG phospholipid, and provides a sustained release of topotecan as an active ingredient. | 2014-05-15 |
20140135358 | Use of FK506 for the Treatment of Pulmonary Arterial Hypertension - A method of reducing pulmonary arterial hypertension in a mammal that employs FK506 is provided. In certain embodiments, the method comprises administering FK506 to a mammal having pulmonary arterial hypertension associated with defective MBPR2 signaling at a dosage sufficient to reduce blood pressure in the pulmonary artery of the mammal. | 2014-05-15 |
20140135359 | METHODS OF DESIGNING, PREPARING, AND USING NOVEL PROTONOPHORES - The present invention provides a computer-assisted method of generating a protonophore requiring the use of a computer including a processor. The method includes: designing the protonophore, calculating, using the processor, an estimated protonophoric activity; producing the protonophore if the estimated protonophoric activity corresponds to an U | 2014-05-15 |
20140135360 | Aryl Derivatives And Uses Thereof - The present invention relates to antimalarial compounds and their use against protozoa of the genus | 2014-05-15 |
20140135361 | ANTI-ALLERGY BENZOCYCLOHEPTATHIOPHENE DERIVATIVES - The present invention provides inhibitors of allergy, and allergic reactions specifically compounds of the present invention are described by the following chemical Formula I: | 2014-05-15 |
20140135362 | INSECTICIDAL N-SUBSTITUTED (6-HALOALKYLPYRIDIN-3-YL)-ALKYL SULFOXIMINES - N-Substituted (6-haloalkylpyridin-3-yl)alkyl sulfoximines are effective at controlling insects. | 2014-05-15 |
20140135363 | PROTON PUMP INHIBITOR FOR USE IN A METHOD OF TREATING DERMATOLOGICAL DISEASES IN CANINE - The present invention relates to a proton pump inhibitor or a pharmaceutically acceptable salt thereof for the treatment of skin diseases in canine patients. The invention also relates to improving the quality of life, improving the general health condition as well as preventing secondary infections in canine patients suffering from skin diseases. Moreover, the present invention also relates to a pharmaceutical composition for topical administration, preferably for use in a method of treating skin diseases and/or improving the general health condition in canine patients, wherein such pharmaceutical formulation comprises a proton pump inhibitor or a pharmaceutically acceptable salt thereof and one or more excipients. | 2014-05-15 |
20140135364 | PESTICIDAL COMPOSITIONS - Pesticidal compositions and their uses are disclosed. | 2014-05-15 |
20140135365 | 2-THIO-1,3,4-OXADIAZOLES AZETIDINE DERIVATIVES AS SPHINGOSINE-1 PHOSPHATE RECEPTORS MODULATORS - The present invention relates to 2-thio-1,3,4-oxadiazoles azetidine derivatives, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals as modulators of sphingosine-1-phosphate receptors. | 2014-05-15 |
20140135366 | ARYL OXADIAZOLE DERIVATIVES AS SPHINGOSINE 1-PHOSPHATE (S1P) RECEPTOR MODULATORS - The present invention relates to aryl oxadiazole derivatives, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals as modulators of sphingosine-1-phosphate receptors. | 2014-05-15 |
20140135367 | Use of Epothilone D in Treating Tau-Associated Diseases Including Alzheimer's Disease - Methods of treating Tau-associated diseases, preferably tauopathies, are described using epothilone D that exhibit good brain penetration, long half-life, and high selective retention in brain, and provides effective therapies in treating tauopathies including Alzheimer's disease. | 2014-05-15 |
20140135368 | SYNTHESIS OF INTERMEDIATES FOR PREPARING ANACETRAPIB AND DERIVATIVES THEREOF - The present invention relates to the field of organic chemistry, more specifically to the synthesis of intermediate compounds which can be used in the synthesis of pharmaceutically active agents such as anacetrapib or derivatives thereof. | 2014-05-15 |
20140135369 | TRPV4 ANTAGONISTS - The present invention relates to spirocarbamate analogs, pharmaceutical compositions containing them and their use as TRPV4 antagonists. | 2014-05-15 |
20140135370 | TREATING CANCER WITH AN HSP90 INHIBITORY COMPOUND - Methods of treating cancer with a compound of formula (I) are disclosed. Also provided are methods of treating a cancer with a KRAS mutation or an ALK+ cancer with a compound of formula (I). Further provided are methods of treating KRAS− mutated or ALK+ NSCLC with a compound of formula (I): | 2014-05-15 |
20140135371 | CHEMICALLY STABLE DISPERSIONS OF PROTHIOCONAZOLE AND PROCESSES FOR PREPARING THEM - Chemically stable aqueous dispersions of prothioconazole and processes for preparing them are provided. The dispersions comprise prothioconazole present in an aqueous medium, and a sulfur-containing compound present in an amount effective to render the dispersion chemically stable. | 2014-05-15 |
20140135372 | COMPOSITIONS AND METHODS OF TREATMENT OF INFLAMMATORY SKIN CONDITIONS USING ALLANTOIN - Embodiments herein provide formulations and methods for treatment of inflammatory skin diseases using allantoin in an amount from about 0.5% to about 15.0% by weight. Inflammatory skin diseases treated by embodiments herein include, without limitation, cutaneous porphyria, sclerodema, epidermolysis bulosa, psoriasis, decubitus ulcers, pressure ulcers, diabetic ulcers, venous stasis ulcers, sickle cell ulcers, ulcers caused by burns, eczema, urticaria, atopic dermatitis, dermatitis herpetiform, contact dermatitis, arthritis, gout, lupus erythematosus, acne, alopecia, carcinomas, psoriasis, rosacea, miliaria, skin infections, post-operative care of incisions, post-operative skin care following any variety of plastic surgery operations, skin care following radiation treatment, care of dry, cracked or aged skin and skin lines as well as other conditions affecting the skin and having an inflammatory component, symptoms thereof, or a combination thereof. Symptoms treated may include pain, inflammation, redness, itching, scarring, skin thickening, milia, or a combination thereof. | 2014-05-15 |
20140135373 | NOVEL ESTERS OF N-ACYLATED DERIVATIVES OF AMINO ACIDS AND ISOSORBIDE, METHOD FOR PREPARING SAME, AND USE THEREOF IN COSMETICS AND AS DRUG - Compound with formula (I), wherein R′ and R″ represent a hydrogen atom, a monovalent radical with formula (IIa), or a monovalent radical with formula (IIb), it being understood that at least one of the R′ or R″ radicals does not represent a hydrogen atom and that when the R′ and R″ radicals do not represent a hydrogen atom, R′ and R″ are identical; method for preparing and using in cosmetics and as a drug. | 2014-05-15 |
20140135374 | Opsin-Binding Ligands, Compositions and Methods of Use - Compounds are disclosed that are useful for treating ophthalmic conditions caused by or related to production of toxic visual cycle products that accumulate in the eye, such as dry adult macular degeneration, as well as conditions caused by or related to the misfolding of mutant opsin proteins and/or the mis-localization of opsin proteins. Compositions of these compounds alone or in combination with other therapeutic agents are also described, along with therapeutic methods of using such compounds and/or compositions. Methods of synthesizing such agents are also disclosed. | 2014-05-15 |
20140135375 | Edible Transgenic Plants as Oral Delivery Vehicles for RNA-Based Therapeutics - Compositions and methods for delivery of therapeutic RNA molecules are disclosed. | 2014-05-15 |
20140135376 | NANOGELS - The present invention relates to a polymer according to Formulas (1) or (2): The present invention further relates to nanogels and nanoparticles made of a polymer according to general Formulas (1) and (2). The nanogels may comprise a biologically active component such as siRNA, miRNA, DNA, an (oligo)peptide or a proteins. | 2014-05-15 |
20140135377 | COMBINATION THERAPY - The invention is based on a finding that silencing PME-1 gene sensitizes cancer cells for apoptosis-inducing activity of certain small molecule chemotherapeutic agents. Thus, the invention is directed to a respective combination therapy, sensitization method and pharmaceutical compositions. | 2014-05-15 |
20140135378 | TARGETING EN2, PAX2, AND/OR DEFB1 FOR TREATMENT OF PROSTATE CONDITIONS - The present invention relates to methods and compositions for treating a prostate condition in a subject. The method comprises administering to the subject a subject effective amount of a pharmaceutical composition having a first agent that inhibits EN2 expression and/or EN2 activity and a second agent that inhibits PAX2 expression and/or PAX2 activity. The pharmaceutical composition may further comprise a third agent that enhances DEFB1 expression or activity. | 2014-05-15 |
20140135379 | METHOD OF FIXING AND EXPRESSING PHYSIOLOGICALLY ACTIVE SUBSTANCE - The present invention provides methods for retaining and expressing physiologically active substances in a target tissue-specific-manner, by administering the physiologically active substances to target submucous tissue. Specifically, the present inventors demonstrated that, when physiologically active substances were directly administered into submucous tissues without using a carrier, the physiologically active substances were effectively and safely retained at the administration sites over long periods without loss and diffusion, and produced the effect acting in a reservoir-like fashion. The physiologically active substances administered as described above were demonstrated to produce the therapeutic effect without having an influence on organs other than the administered organ. | 2014-05-15 |
20140135380 | Small molecule conjugates for intracellular delivery of nucleic acids - The invention provides use of novel compounds for delivery of nucleic acids, and conjugates of these compounds with nucleic acids. Further novel design criteria for chemically stabilized siRNA particular useful when covalently attached to said compounds and co-administered with a delivery polymer to achieve mRNA knock down in vivo are disclosed therein. | 2014-05-15 |
20140135381 | Small molecule conjugates for intracellular delivery of biologically active compounds - The invention provides novel compounds and conjugates of these compounds useful for the delivery of biologically active substances. Further novel design criteria for chemically stabilized siRNA particular useful when covalently attached to a delivery polymer to achieve in vivo mRNA knock down are disclosed therein. | 2014-05-15 |
20140135382 | cDNA-DERIVED NUCLEIC ACIDS ENCODING RED-SHIFTED CHANNELRHODOPSINS - Methods and compositions are used to identify and characterize new channelrhodopsins derived from algae and several of which are red-shifted. The rhodopsin domain of these red-shifted channelrhodopsins can be cloned and expressed in mammalian systems and used in optogenetic applications and as therapeutic agents. Also provided are methods and compositions for use in red-shifting the absorbance maxima of channelrhodopsins in order to improve their utility for use in vivo. | 2014-05-15 |
20140135383 | SDF-1 DELIVERY FOR TREATING ISCHEMIC TISSUE - A method of treating a cardiomyopathy in a subject includes administering directly to or expressing locally in a weakened, ischemic, and/or peri-infarct region of myocardial tissue of the subject an amount of SDF-1 effective to cause functional improvement in at least one of the following parameters: left ventricular volume, left ventricular area, left ventricular dimension, cardiac function, 6-minute walk test, or New York Heart Association (NYHA) functional classification. | 2014-05-15 |
20140135384 | ENDOGENOUS RETROVIRUS POLYPEPTIDES LINKED TO ONCOGENIC TRANSFORMATION - HERV-K human endogenous retroviruses show up-regulated expression in tumors. In particular, splicing events in the env region generate a series of transcripts which utilize the +2 reading frame, relative to the env reading frame. The proteins show activity typical of transcriptional regulators, and they also have oncogenic potential. Two related proteins, PCAP2 and PCAP3, are strongly associated with breast cancer and prostate cancer, respectively. PCAP4 stimulates cell division. These proteins can be used in cancer diagnosis and therapy, and are also drug targets e.g. for adjuvant therapy. The identification of these splice products is remarkable because full sequence information has been available for HERV-K viruses since 1986. | 2014-05-15 |
20140135385 | RYANODINE RECEPTOR INHIBITORS FOR TREATMENT OF T-CELL MEDIATED DISORDERS - This invention relates to methods of treating T-cell mediated diseases or disorders in human or animal subjects, such as autoimmune diseases and chronic graft versus host disease in humans and animals. In particular, the methods comprise administering to the human or animal patient a pharmaceutical composition comprising a ryanodine receptor inhibitor. | 2014-05-15 |
20140135386 | METHOD FOR TREATING ATHEROSCLEROSIS OR RESTENOSIS USING MICROTUBULE STABILIZING AGENT - The present invention is a method of preventing or reducing atherosclerosis or restenosis, and a pharmaceutical preparation used therefore. In particular, it is a method of preventing or reducing atherosclerosis or restenosis after arterial injury by treatment with a low dose of a microtubule stabilizing agent such as taxol or a water soluble taxol derivative. The low dose used in the present invention prevents artery blockage while minimizing any negative side effects associated with the drug. | 2014-05-15 |
20140135387 | USE OF EQUOL OF TREATING ANDROGEN MEDIATED DISEASES - Equol (7-hydroxy-3(4′hydroxyphenyl)-chroman), the major metabolite of the phytoestrogen daidzein, specifically binds and blocks the hormonal action of 5α-dihydrotestosterone (DHT) in vitro and in vivo. Equol can bind circulating free DHT and sequester it from the androgen receptor, thus altering growth and physiological hormone responses that are regulated by androgens. These data suggest a novel model to explain equol's biological properties. The significance of equol's ability to specifically bind and sequester DHT from the androgen receptor have important ramifications in health and disease and may indicate a broad and important usage for equol in the treatment and prevention of androgen-mediated pathologies. Thus, equol can specifically bind DHT and prevent DHT's biological actions in physiological and pathophysiological processes. | 2014-05-15 |
20140135388 | Self-Emulsifying Active Ingredient Formulation and the Use of This Formulation - The present invention relates to self-emulsifying formulations based on an active ingredient component and a formulation base with a lipid component and with a binder component and to the use of this formulation as dosage form in the life science sector. The invention also describes a process for producing self-emulsifying formulations by mixing the formulation components to form a plastic mixture and, where appropriate, to manufacture the formulations as dosage form advantageously by use of melt extrusion. The formulations spontaneously form emulsions in water or aqueous media. | 2014-05-15 |
20140135389 | QUINONE BASED NITRIC OXIDE DONATING COMPOUNDS - The present invention relates to nitric oxide donor compounds having a quinone based structure, to processes for their preparation and to their use in the treatment of pathological conditions where a deficit of NO plays an important role in their pathogenesis. | 2014-05-15 |
20140135390 | Modified Platinum Compounds - Platinum compounds, modified by conjugation with thiol-containing moieties, such as cysteine or N-acetyl cystein (NAC), and pharmaceutical compositions including the modified platinum compounds. Methods for treatment of a malignancy including administering and activating the modified platinum compounds. | 2014-05-15 |
20140135391 | METHOD FOR MANUFACTURING REFINED CHLOROGENIC ACIDS COMPOSITION - Provided is a method for producing a chlorogenic acids composition having a reduced caffeine content and good taste and favor, capable of efficiently recovering high purity of chlorogenic acids from a chlorogenic acids-containing composition. The method for producing a purified chlorogenic acids composition comprises a step A of bringing a chlorogenic acids-containing composition into contact with a cation exchange resin; a step B of bringing the liquid obtained in the step A into contact with an anion exchange resin; and a step C of bringing an eluent into contact with the anion exchange resin after the step B. | 2014-05-15 |
20140135392 | METHODS FOR THE TREATMENT OF SIALORRHEA - The present invention provides safe and effective methods for the treatment of sialorrhea (excessive drooling) by administering an effective amount of N-desethyloxybutynin, or an optical R- or S-isomer thereof. N-desethyloxybutynin is a metabolite of oxybutynin and has higher affinity for receptors present in the parotid glands (the salivary glands in humans) than oxybutynin. | 2014-05-15 |
20140135393 | SUBSTITUTED CATHECHOLS AS INHIBITORS OF IL-4 AND IL-5 FOR THE TREATMENT BRONCHIAL ASTHMA - The present invention relates to compounds of general formula 1 for the treatment of bronchial asthma by inhibition of IL-4 or IL-5 pathway inhibition. The present invention also relates to the use of compound of general formula 1 for the treatment of bronchial by inhibition of IL-4 or IL-5 pathway. The present invention also relates to the method of treating asthma by inhibition of IL-4 or IL-5 pathway by administration of compound or said composition through oral, intranasal, route or by inhalation to a mammal in need thereof. Compound of general formula 1 may be used for reducing perivascular and peribronchial inflammation. | 2014-05-15 |
20140135394 | METHOD OF PREPARATION AND COMPOSITION OF ANTIMICROBIAL ICE - Composition and method for production of peroxycarboxylic acid solutions for various disinfection and cleaning compositions that utilizes non-equilibrium peroxycarboxylic acid. More specifically compositions comprise peracetic acid (PAA) and methods for making non-equilibrium PAA are provided. Frozen compositions useful as antimicrobial ice are provided. | 2014-05-15 |
20140135395 | GASTRIC RETENTIVE GABAPENTIN DOSAGE FORMS AND METHODS FOR USING SAME - Provided is a method of treating a patient suffering from a pain state by administering to the patient a gastric retentive dosage form of gabapentin that is capable of administration in once-daily or twice daily dosing regimens. By reducing the need to administer gabapentin from the thrice-daily administrations characteristic of immediate release gabapentin, the gastric retentive gabapentin dosage forms provided herein have the advantages of improving patient compliance for gabapentin treatment. In addition to the foregoing, the gastric retentive gabapentin dosages forms also exhibit decreased blood plasma concentrations and increased bioavailability throughout the dosing regimen. | 2014-05-15 |
20140135396 | Treatment of Acetaminophen-Induced Liver Damage by the Administration of Modulators of Nitric Oxide - The invention is directed to the treatment of patients at risk for liver damage due to the overingestion of acetaminophen by administering agents that increase hepatic levels of nitric oxide. | 2014-05-15 |
20140135397 | HALOGENATED PHENOLS FOR DIAGNOSTICS, ANTIOXIDANT PROTECTION AND DRUG DELIVERY - The present invention provides compositions and methods for the targeted delivery, release and/or formation of a drug compound at a target site(s) within the body of an individual, such as a diseased and/or inflamed tissue in the body of the individual. These compositions may comprise a halogenated phenol ring cleavably linked to a core structure of a drug compound. Due to the variety of substituents that may be utilized in forming the different types of linkages, numerous examples of drug compounds linked to a halogenated phenol ring are proposed. The present invention further provides compositions comprising halogenated phenol starting compounds that do not undergo cleavage during a dehalogenation reaction to form a drug compound in a targeted tissue when administered to an individual. Methods of administering these non-cleaving compounds are further provided. | 2014-05-15 |
20140135398 | Antioxidant Producing Bacterium and Uses Thereof - Bacterial strains are provided that can be isolated from the microflora of lowbush blueberry ( | 2014-05-15 |
20140135399 | NOVEL POLYMORPHS AND SALTS - Novel polymorphic forms and salts of 1-(3′,4′-dichloro-2-fluorobiphenyl-4-yl)cyclopropanecarboxylic acid are useful for the prevention or treatment of Alzheimer's Disease. | 2014-05-15 |
20140135400 | NOVEL ANTAGONISTS OF THE GLUCAGON RECEPTOR - The present invention provides for novel compounds of Formula (I) and pharmaceutically acceptable salts and co-crystals thereof which have glucagon receptor antagonist or inverse agonist activity. The present invention further provides for pharmaceutical compositions comprising the same as well as methods of treating, preventing, delaying the time to onset or reducing the risk for the development or progression of a disease or condition for which one or more glucagon receptor antagonist is indicated, including Type I and II diabetes, insulin resistance and hyperglycemia. The present invention also provides for processes of making the compounds of Formula I, including salts and co-crystals thereof, and pharmaceutical compositions comprising the same. | 2014-05-15 |
20140135401 | ARACHIDONIC ACID ANALOGS AND METHODS FOR ANALGESIC TREATMENT USING SAME - The present invention provides arachidonic acid (AA) analogs and compositions containing those analogs as active agents for use in analgesic treatments. Various methods of manufacturing the inventive compounds are provided and pharmaceutical formulations, including injectable and oral dosages, are described. Certain analogs are additionally useful as antipyretic compositions and in related fever reducing treatments. | 2014-05-15 |
20140135402 | CYCLODODECADIENONE DERIVATIVES AS PERFUMING INGREDIENTS - The present invention relates to compounds of Formula (I), wherein one R group is a hydrogen atom and the other is a hydrogen atom or a C | 2014-05-15 |
20140135403 | USE OF CYCLOHEXANEHEXOL DERIVATIVES IN THE TREATMENT OF OCULAR DISEASES - The present invention relates to methods of treating ocular diseases in a subject by administering to the subject a therapeutically effective amount of one or more cyclohexanehexyl derivatives, or salts thereof, or a medicament comprising a cyclohexanehexol derivative and a pharmaceutically acceptable carrier. More specifically, the invention provides a medicament comprising at least one cyclohexanehexyl derivative of formula (III) or (IV) useful in preventing or treating ocular diseases, by modulating the folding, oligomerization or aggregation of amyloid β in ocular cells. Methods of administration of these medicaments include systemic, transpleural, oral, intravenously, intraarterial, intramuscular, topical, via inhalation, transdermal, subcutaneous, intraperitoneal, gastrointestinal, and directly to the eye or tissues surrounding the eyes. Formulae (III), (IV). | 2014-05-15 |
20140135404 | SESQUITERPENES FOR ANTIFUNGAL APPLICATIONS - Bicyclic sesquiterpene compounds exhibiting antifungal characteristics are formulated into antifungal compositions for use in the treatment of fungal infections in humans, animals, and plants. Particularly, sesquiterpene alcohols derived from drimane have been discovered to possess broad-spectrum antifungal characteristics. Exemplary antifungal sesquiterpene compounds include albicanol and drimenol, which have been shown effective against a number of pathogenic fungi. | 2014-05-15 |
20140135405 | WATER-IN-SILICONE OIL MACROEMULSION COSMETIC COMPOSITION - A water-in-silicone oil macroemulsion cosmetic composition of waterdrop quick break type is provided. The silicone oil phase part contains a partly crosslinked emulsifiable silicone elastomer, a partly crosslinked non-emulsifiable silicone elastomer, and silicone oil, and the aqueous phase part contains glycerin as a freeze stabilizer and at least one member selected from polyols and lower alcohols and/or at least one member selected from organic acid salts and inorganic salts as a mixture of freeze stabilizers. The cosmetic composition instantaneously releases water upon application on the skin. The cosmetic composition is stable at the extremely low temperature of −20° C., and it retains its dispersion stability even after repeated freezing and thawing, and accordingly, and it can be used in a variety of cosmetic product. | 2014-05-15 |
20140135406 | WATER-IN-SILICONE OIL MACROEMULSION COSMETIC COMPOSITION - A water-in-silicone oil (W/S) macroemulsion cosmetic composition of waterdrop quick break type is provided. The silicone oil phase part (S) contains a partly crosslinked emulsifiable silicone elastomer, a partly crosslinked non-emulsifiable silicone elastomer, and silicone oil, and the aqueous phase part (W) contains 1,3-butylene glycol and a lower alcohol, and also, at least one member selected from the group consisting of organic acid salts, inorganic salts, and polyhydric alcohols excluding glycerin and 1,3-butylene glycol as a freeze stabilizer at a predetermined composition. The cosmetic composition instantaneously releases water upon application on the skin. The cosmetic composition is stable at the extremely low temperature of −20° C., and it retains its dispersion stability even after repeated freezing and thawing, and accordingly, it can be used in a variety of cosmetic product. | 2014-05-15 |
20140135407 | BIODEGRADABLE NANOCOMPOSITES WITH ENHANCED MECHANICAL PROPERTIES FOR SOFT TISSUE ENGINEERING - The present invention is directed to a novel poly(diol citrates)-based nanocomposite materials created using completely biodegradable and biocompatible polymers that may be used in tissue engineering. More specifically, the specification describes methods and compositions for making and using nanocomposites comprised of citric acid copolymers and polymers including but not limited to poly(L-lactic acid) (PLLA) and poly(lactic-co-glycolic acid) (PLGA). | 2014-05-15 |
20140135408 | SILICONE CONTAINING MONOMERS WITH HYDROPHILIC END GROUPS - Silicone containing reactive monomers with hydrophilic end-groups of formula I useful in the manufacture of biocompatible medical devices are disclosed, wherein R | 2014-05-15 |
20140135409 | PROCESS FOR REFORMING HYDROCARBONS - The invention relates to a process for the production of synthesis gas by the use of autothermal reforming in which tail gas from downstream Fischer-Tropsh synthesis is hydrogenated and then added to the autothermal reforming stage. | 2014-05-15 |
20140135410 | HYDROCARBON SYNTHESIS REACTION APPARATUS, START-UP PROCESS THEREOF, AND HYDROCARBON SYNTHESIS REACTION SYSTEM - The hydrocarbon synthesis reaction apparatus is provided with a synthesis gas supply line in which a synthesis gas is compressed and supplied by a first compressor, a reactor configured to accommodate a catalyst slurry, a gas-liquid separator configured to separate an unreacted synthesis gas and hydrocarbons discharged from the reactor into a gas and a liquid, a first recycle line in which the unreacted synthesis gas after separation into a gas and a liquid is compressed and recycled into the reactor by a second compressor, and a second recycle line configured to recycle a residual unreacted synthesis gas after separation into a gas and a liquid into the inlet side of the first compressor at the time of start-up operation when the synthesis gas is gradually increased in the amount to be introduced. | 2014-05-15 |
20140135411 | CARBON SUPPORTED COBALT AND MOLYBDENUM CATALYST - The present invention relates to a catalyst composition comprising cobalt molybdenum and optionally one or more elements selected from the group consisting of alkali metals and alkaline earth metals on a carbon support wherein said cobalt and molybdenum are in their metallic form. It was surprisingly found that the selectivity for alcohols can be increased by using the carbon supported cobalt molybdenum catalyst as described herein in a process for producing alcohols from a feed stream comprising hydrogen and carbon monoxide. Furthermore, it was found that the catalyst of the present invention has a decreased selectivity for CO2 and can be operated at relatively low temperature when compared to conventional catalysts. Moreover, a method for preparing the carbon supported cobalt molybdenum catalyst composition and a process for producing alcohols using said carbon supported cobalt molybdenum catalyst composition is provided. | 2014-05-15 |
20140135412 | METHOD AND APPARATUS FOR REMOVING FOREIGN SUBSTANCES FROM POLYMERS - Method for removing a foreign substance from a polymer composition including subjecting a polymer composition to a medium selected from the group comprising chemical reagents, electron beam radiation, electromagnetic radiation, or combinations thereof, removing the transformed foreign substance from the polymer composition, where the foreign substance is by subjecting the polymer composition to the medium at least partially transformed into a form that facilitates removal from the polymer composition. Also, an apparatus for removing a foreign substance from a polymer composition including a device for subjecting a polymer composition to a medium selected from the group comprising chemical reagents, electron beam radiation, electromagnetic radiation, or combinations thereof, and a device for removing the transformed foreign substance from the polymer composition, where the foreign substance is by the device for subjecting the polymer composition to the medium at least partially transformed into a form that facilitates removal from the polymer composition. | 2014-05-15 |
20140135413 | PHOTO-CURABLE ORGANIC-INORGANIC HYBRID RESIN COMPOSITION - The present invention relates to a photo-curable organic-inorganic hybrid composition, more particularly to a photo-curable organic-inorganic hybrid resin composition having superior physical properties such as UV resistance, chemical resistance, light transmittance, adhesive property, insulating property, heat resistance, flatness and water resistance and in particular, having excellent heat resistance and adhesive property enabling the composition to endure a thermal deformation caused by a processing temperature change during post-process after a film is cured. Thus, the composition of the invention is suitable for use as an insulating material and an encapsulating material for a protective film of optical devices including display devices and semiconductors. | 2014-05-15 |
20140135414 | PREPARATION OF POLYMERIZABLE COMPOSITIONS - Processes for modifying the viscosity of medically useful polymerizable compositions are described. The processes are carried out by providing an oxygen-free fluid composition comprising one or more polymerizable monomers and subsequently irradiating the composition with a controlled dose of high-energy radiation sufficient to effect a desired viscosity increase. Compositions produced via these process are also disclosed. | 2014-05-15 |
20140135415 | ULTRA HIGH MOLECULAR WEIGHT POLYETHYLENE ARTICLES AND METHODS OF FORMING ULTRA HIGH MOLECULAR WEIGHT POLYETHYLENE ARTICLES - The present invention generally provides implantable articles and methods of forming implantable articles from a crosslinked ultrahigh molecular weight polyethylene (“UHMWPE”) blend stabilized with Vitamin E. The crosslinked UHMWPE blend may be prepared by combining the UHMWPE material and vitamin E prior to irradiating the UHMWPE blend with electron beam radiation at a sufficient radiation dose rate to induce crosslinking. The crosslinked UHMWPE blend may be incorporated into a variety of implants, and in particular, into endoprosthetic joint replacements | 2014-05-15 |
20140135416 | SILICONE RUBBER COMPOSITION, SILICONE RUBBER MOLDED ARTICLE, AND PRODUCTION METHOD THEREOF - A UV curable silicone rubber composition is provided. The composition does not undergo curing failure, foaming, and other undesirable conditions even if a water-containing inorganic filler such as zeolite were added. A UV curable silicone rubber composition comprising (A) 100 parts by weight of an organopolysiloxane having at least 2 alkenyl groups per molecule represented by the average compositional formula (I): R | 2014-05-15 |
20140135417 | TRANSPARENT ADHESIVE/BONDING AGENT AND HIGH-TEMPERATURE MAINTAINING STICKY AGENT - Provided is a transparent pressure-sensitive adhesive agent convertible into an adhesive agent that allows adherends to be instantly fixed to each other, allows the adherends to be reattached to each other, is excellent in processability such as being able to be cut into a sheet shape, is not peeled from the adherends even when exposed to a high-temperature atmosphere such as one in a fire, and has such transparency as to hardly impair the designs of the adherends. The transparent pressure-sensitive adhesive agent convertible into an adhesive agent has pressure-sensitive adhesive property before being sintered, and has adhesive property after being sintered. | 2014-05-15 |
20140135418 | POLYMETHYLMETHACRYLATE BONE CEMENT - The subject matter of the invention is a curable composition for use as bone cement, in particular for augmentation of osteoporotic bone tissue, comprising at least one organic polymer and at least one monomer for radical polymerisation, at least one particulate inorganic additive having a BET surface of at least 40 m | 2014-05-15 |
20140135419 | COMPOSITION FOR INKS AND COATINGS WITH HIGH LAMINATION BOND STRENGTH - A composition obtained by the following steps (i) furnishing a composition (C) comprising an emulsion polymer (a) and thereafter (ii) adding to said composition (C) a composition comprising a water-soluble polymer (b) comprising ether groups, wherein said water-soluble polymer (b) does not comprise carboxylate groups and, said water-soluble polymer (b) has a solubility in water of at least 50 g/l. A method of making a such a composition and the use of such for water based coatings or inks is described. | 2014-05-15 |
20140135420 | Ready-Mix Joint Compounds Using Non-Uniformly Substituted Carboxylmethylcellulose - The presently disclosed and claimed inventive concept(s) relates generally to a carboxymethylcellulose (CMC) system for use in ready-mix joint compounds. More specifically, the presently disclosed and claimed inventive concept(s) relates to a non-uniformly substituted (“blocky”) CMC system for use as an efficient thickener and rheology modifier for ready-mix joint compounds and the use of a reduced amount of clay for improving the joint compounds. | 2014-05-15 |
20140135421 | TREATED INORGANIC PIGMENTS HAVING REDUCED PHOTOACTIVITY AND IMPROVED ANTI-MICROBIAL PROPERTIES AND THEIR USE IN COATING COMPOSITIONS - The disclosure provides a coating composition comprising a treated inorganic particle having reduced photoactivity and improved anti-microbial properties, wherein the treated inorganic particle comprises: an inorganic core particle; a first treatment of a silicon compound, wherein the silicon compound is added in a single step; and a second treatment comprising co-precipitated zinc oxide and alumina. | 2014-05-15 |
20140135422 | FOULING CONTROL COATING COMPOSITIONS - The present application discloses a fouling control cured paint coat comprising a polysiloxane-based binder matrix and one or more biocides, said binder matrix having included as a part thereof hydrophilic oligomer/polymer moieties, wherein the weight ratio between the hydrophilic oligomer/polymer moieties and the one or more biocides is in the range 1:0.02 to :20, and wherein ≧50% of the binder system is polysiloxane parts. The application further discloses a marine structure comprising on at least a part of the outer surface thereof an outermost coating of the cured paint coat. Moreover, the application discloses the use of the combination of one or more polysiloxane components modified with hydrophilic oligomer/polymer moieties and one or more biocides, wherein the weight ratio between the hydrophilic oligomer/polymer moieties and the one or more biocides is in the range 1:0.02 to :20, for improving the antifouling properties of a polysiloxane based coating composition. | 2014-05-15 |
20140135423 | Stone-Made Green Energy Paper and Method for Making the Same - The present invention relates to relates to a stone-made green energy paper and a method for making the same, wherein the stone-made green energy paper is made of some non-toxic materials consisting of a stone powder, a pure-white silica powder and a non-toxic resin. This stone-made green energy paper can be used as a base paper for further machining to a green energy writing paper or a green energy art-using paper. The stone-made green energy paper includes the advantages of good ink absorption, high waterproof, high strength, high folding performance, and free-pollution. Moreover, the most important is that the stone-made green energy paper has no CaCo | 2014-05-15 |
20140135424 | RUBBER COMPOSITION AND TIRE WITH COMPONENT COMPRISED OF POLYISOPRENE RUBBER AND SOYBEAN OIL - This invention relates to a rubber composition and tire with component comprises of such rubber composition comprised of a combination of cis 1,4-polyisoprene rubber, desirably natural rubber, and low level of soybean oil. | 2014-05-15 |
20140135425 | RUBBER COMPOSITION FOR TREAD, AND PNEUMATIC TIRE - Provided are a rubber composition for a tread, capable of improving the fuel economy and abrasion resistance in a balanced manner while achieving a good appearance and a good cure rate; and a pneumatic tire containing the rubber composition. The present invention relates to a rubber composition for a tread, including: a solution-polymerized styrene-butadiene rubber, carbon black, silica, and polyethylene glycol, wherein a rubber component of the rubber composition contains 60 mass % or more of the solution-polymerized styrene-butadiene rubber based on 100 mass % of the rubber component, and the rubber composition includes, per 100 parts by mass of the rubber component, 10 parts by mass or less of the carbon black, 50 parts by mass or more of the silica, and 0.1 to 3.5 parts by mass of the polyethylene glycol. | 2014-05-15 |
20140135426 | RESIN COMPOSITION - There is provided a resin composition including a copolymer having structural units of Formula (1), Formula (2), and Formula (3), and a solvent; or a resin composition including a copolymer having structural units of Formula (1), Formula (4), and Formula (5), and a solvent. | 2014-05-15 |
20140135427 | PROCESS FOR DRYING CONCRETE DISPERSANTS - A process for the production of a solid dispersant for a hydraulically binding composition includes the steps of: providing at least one first polymer, which is a comb polymer having a polymer backbone comprising carboxyl groups; providing at least one second polymer, which is a condensate of, at least, an aromatic compound and formaldehyde; or a lignosulfonate; preparing an aqueous solution comprising the first and the second polymer; and spray-drying the aqueous solution to obtain the solid dispersant. | 2014-05-15 |
20140135428 | Polymerizate Comprising a Macromonomer - The present invention relates to a polymerizate in the form of an aqueous polymer dispersion, the polymerizate being obtainable by radical polymerization of monomers in an aqueous medium in the presence of a free radical initiator and a protective colloid, wherein the monomers comprise a) 50-99.99 wt. % of at least one vinyl monomer chosen from the group of vinyl esters, (meth)acrylic esters, vinyl aromatic compounds, vinyl halides, and olefins, and b) 0.01-30 wt. % of at least one macromonomer M, the macromonomer M being a reaction product of components (i), (ii), and (iii), said —component (i) having at least one olefinically unsaturated group and at least one hydroxyl, amine and/or thiol group, —component (ii) being a di- or triisocyanate, and —component (iii) having at least two terminal groups selected from hydroxyl, amine and/or thiol groups, c) 0-20 wt % of at least one vinyl monomer with at least one functional group, wherein the monomers a), b), and c) sum up to 100 wt. % of total monomers employed. The invention further provides a process to prepare the polymerizate, water-redispersible polymer powders obtainable from the polymerizate, and building material compositions containing the polymerizate and/or the water-redispersible polymer powders. | 2014-05-15 |
20140135429 | HYDRAULIC SETTING ADHESIVE WITH IMPROVED OPEN TIME - A hydraulic setting adhesive containing a hydraulic binder, fillers, a water retention agent, a sulfoalkylester surfactant, and optionally a redispersible polymer powder and/or a polymer dispersion, wherein the surfactant is represented by the formula of MSO | 2014-05-15 |